Song, Yuyu http://orcid.org/0000-0002-9196-1610
Subramanian, Kartik http://orcid.org/0000-0002-6900-8882
Berberich, Matthew J. http://orcid.org/0000-0003-2196-3757
Rodriguez, Steven http://orcid.org/0000-0002-2708-5791
Latorre, Isabel J. http://orcid.org/0000-0003-0638-1783
Luria, Catherine M. http://orcid.org/0000-0003-0134-5804
Everley, Robert http://orcid.org/0000-0003-0460-5229
Albers, Mark W. http://orcid.org/0000-0001-7855-3455
Mitchison, Timothy J. http://orcid.org/0000-0001-7781-1897
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Article History
Received: 22 June 2018
Accepted: 21 December 2018
First Online: 19 February 2019
Competing interests
: Peter K. Sorger is a founder, SAB member and equity holder in Merrimack Pharmaceutical and Glencoe Software; he is a member of the Board of Directors of Applied Biomath and the SAB of RareCyte Inc. In the last five years the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript.